AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00945282
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a capsule with no drug in it.
Trial: NCT00945282
Drug: GSK2248761
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2248761 10 mg -20 mg or 40 mg - 90 mg once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.
Trial: NCT02314325
Drug: ADVATE [Antihemophilic Factor (Recombinant)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Arm 1 prior patients will be dosed as per body weight 20-40 IU/kg 5-7 infusions per fortnight
Trial: NCT02314325
Drug: ADVATE [Antihemophilic Factor (Recombinant)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Arm 2 patients who have completed arm 1 will cross over onto an individualised PK tailored alternate day dosing regimen
Trial: NCT03393117
Drug: Oral Narcotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral narcotics will be offered when the patient's diet is advanced as tolerated, typically post-operative day 1.
Trial: NCT00152893
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04354376
Drug: Loop diuretics, thiazides, dihydropyridines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loop diuretics, thiazides, or dihydropyridines dispensing claim is used as the reference
Trial: NCT00890825
Drug: AZD6244
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsules, 75mg twice daily
Trial: NCT00890825
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02707913
Drug: Norvasc Tablet 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norvasc Tablet 10mg will be used as a comparator drug for the BE study
Trial: NCT01370707
Drug: CJ-30001/CJ-30002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6/1500mg\~0.9/1500mg/day, 24weeks
Trial: NCT01879683
Drug: LiRIS® 400 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LiRIS® 400 mg is a drug-device combination product which is placed in the bladder during cystoscopy, remains in the bladder for up to 14 days gradually releasing lidocaine, and removed from the bladder via cystoscopy.
Trial: NCT00777816
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of placebo on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection.
Trial: NCT04507945
Drug: Nutritional Therapy, Metabolic Disorder, Regular
RxNorm normalized name: nutritional therapy, metabolic disorder, regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to the result reported by Byrne, Wilmore, etc. in 1992 \~ 1995, the use of growth hormone, glutamine, modified diet and other measures proposed intestinal rehabilitation treatment. Then, check the patient's quality of life survey, nutritional status, inflammation indicators and other changes every three months, and use metabolomics and microbiomic tools to detect changes in the patient's nutritional metabolism, intestinal microecology, etc., and adjust the patient's nutritional treatment and microecological treatment based on the results Program.
Trial: NCT00917241
Drug: MMI
RxNorm normalized name: Rommix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMI treatment with titration regimen for 18 months, initial dosage was 20 mg/d.
Trial: NCT00076414
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00758433
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch q.d. 24 hours for 7 days
Trial: NCT00741052
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 gm Azithromycin single dose
Trial: NCT01919229
Drug: LEE011 (ribociclib)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib was supplied in 200 mg hard gelatin capsules for oral use.
Trial: NCT01353963
Drug: desvenlafaxine succinate
RxNorm normalized name: Desvenlafaxine Succinate
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg tablet once daily
Trial: NCT00507169
Drug: SVT-40776
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03616470
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline, 0.9% Sodium Chloride
Trial: NCT01204749
Drug: AMG 386 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly Intravenous (IV) placebo 15 mg/kg
Trial: NCT01929590
Drug: PEG-3350 group 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: split-dose (PEG-3350; 2 L the day before 17:00-19:00 h and 2 L same day of the procedure 06:00-08:00 am)
Trial: NCT01929590
Drug: PEG-3350 group 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-3350; PEG-4 L the day previous of the study, starting at 17:00 and finishing at 21:00 h
Trial: NCT01929590
Drug: PEG-3350 group 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low-volume 2 L PEG-solution (same day of the procedure 06:00-08:00 am)
Trial: NCT02109640
Drug: Targinact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative analgesia
Trial: NCT00297674
Drug: Intravenous Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02808585
Drug: PB1046 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four weekly subcutaneous injections of PB1046.
Trial: NCT02808585
Drug: Placebo Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four weekly subcutaneous injections of placebo.
Trial: NCT00113906
Drug: melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03703778
Drug: Androgen deprivation therapy - GnRH agonist
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
Trial: NCT03703778
Drug: Androgen deprivation therapy - GnRH antagonist
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
Trial: NCT02519023
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine.
Trial: NCT02519023
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: all individuals will receive scheduled acetaminophen (1 gram every 6 hours),
Trial: NCT02519023
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: all individuals will receive scheduled ibuprofen (800 mg every 8 hours)
Trial: NCT01401985
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules
Trial: NCT00617201
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral dosing - matched placebo
Trial: NCT00626275
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00626275
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00495729
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive matching placebo tablets to SB-649868 orally 1 hour prior to simvastatin administration.
Trial: NCT00495729
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive Simvastatin 10 mg tablets orally.
Trial: NCT03599453
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by mouth
Trial: NCT04281108
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally disintegrating tablet.
Trial: NCT00744926
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sc, once weekly
Trial: NCT02910635
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01803555
Drug: SYMBICORT® TURBOHALER®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbicort Turbohaler will be administered per dose and schedule specified in the arm.
Trial: NCT01803555
Drug: SYMBICORT placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYMBICORT placebo multi-dose dry powder inhaler (DPI) identical in appearance to SYMBICORT TURBOHALER will be administered per dose and schedule specified in the arm.
Trial: NCT01803555
Drug: SPIROMAX Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPIROMAX Placebo multi-dose dry powder inhaler (DPI) identical in appearance to BF SPIROMAX will be administered per dose and schedule specified in the arm.
Trial: NCT02302586
Drug: Patient Controlled Analgesia (IV PCA)
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV morphine patient controlled analgesia (PCA) is being used in the postoperative period for 48 hours. Basal infusion: 0.3 mg/kg/h, Bolus: 1 mg, Lock-out time: 20 min, 4-h limit: 10-12,5 mg
Trial: NCT02576223
Drug: Isotonic Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline injected perineural at the suprascapular nerve.
Trial: NCT02576223
Drug: PCA-pump
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA (Patient controlled analgesia) pump with the following settings:~Age \> 70 years or weight \< 60 kg: bolus dose 2,5 mg i.v. morphine, 15 minutes lockout Age \< 70 years and weight \> 60 kg: bolus dose 5 mg i.v. morphine, 15 minutes lockout Lockout time 15 minutes.
Trial: NCT01721161
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses)
Trial: NCT00861510
Drug: ON01910 Na
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00174434
Drug: SU011248
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SU011248 provided as capsules. The starting dose is 25 mg orally, daily in a continuous regimen beginning on day 2. Dose rest for 1 week is allowed. Dose escalation to 37.5 mg po OD is allowed within the constraints of acceptable toxicity parameters. Dosing will continue for 1 year or until disease progression or unacceptable toxicity, whichever comes first.
Trial: NCT01420549
Drug: Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tables containing: Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.
Trial: NCT00376519
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush and mesna (MT(S)9006) on day -8 and -7 one hour after fludarabine infusion.
Trial: NCT03775798
Drug: Direct antiviral agents for hepatitis C
RxNorm normalized name: hepatitis C virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-acting antivirals for hepatitis C
Trial: NCT02252328
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 80mg once daily
Trial: NCT02252328
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets once daily
Trial: NCT02940561
Drug: Methotrexate - Amneal
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate Tablets, USP contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate, USP and are round, biconvex, yellow tablets, scored in half on one side, engraved with A above the score and 1 below
Trial: NCT02940561
Drug: Methotrexate - DAVA
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate Tablets, USP contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate and are round, convex, yellow tablets, scored in half on one side, engraved with M above the score, and 1 below
Trial: NCT00774852
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg intravenous infusion every 2 weeks for 12 weeks
Trial: NCT00774852
Drug: azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 mg/kg/day orally from weeks 12-28; continue until week 52 if only partial response observed at week 24
Trial: NCT00774852
Drug: azathioprine placebo
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral capsule, daily from weeks 28 to 52, only if complete response observed at week 24
Trial: NCT01251354
Drug: BN83495
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of 40 mg, oral, daily until progression or death or unacceptable toxicity develops
Trial: NCT00832091
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There was one concentration of placebo gel for topical administration to the placebo group. The concentration was 0.0% weight/weight (w/w) thymosin beta 4 gel applied once daily for up to 84 days
Trial: NCT00148759
Drug: LPV/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPV/r 800/200 mg once daily
Trial: NCT02753946
Drug: ZTI-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6g ZTI-01 intravenous infusion TID q8 hours
Trial: NCT04001712
Drug: Caffeine Citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: caffeine citrate is given early to preterm neonates in need of respiratory support
Trial: NCT03697876
Drug: PRO-165
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRO-165 Chondroitin sulfate 0.18% / sodium hyaluronate 0.2%, ophthalmic gel. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.
Trial: NCT03697876
Drug: Artelac
RxNorm normalized name: Artelac Nighttime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artelac® Nightime Gel. 0.2% Carbomer, ophthalmic gel. Made in Germany by: Dr. Gerhard Mann Chem Pharm. Imported and marketed by: Bausch \& Lomb México, S.A. de C.V.
Trial: NCT02741245
Drug: Rosuvastatin 2.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02741245
Drug: Placebo for Rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02784795
Drug: LY3039478
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02784795
Drug: LY3023414
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03980730
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsule administered orally, once daily
Trial: NCT01949974
Drug: Standard Palliative Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Palliative Chemotherapy, depending on type cancer.
Trial: NCT00605228
Drug: COLOPEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4L Drug
Trial: NCT00004127
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004127
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01365286
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo b.i.d. for 5 days and Ivabradine 7,5 mg b.i.d. for 5 days (Placebo-Ivabradine)
Trial: NCT02407223
Drug: Group 1: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo SC at Weeks 0, 4, 16, and 20. At Week 24, all participants (except those who early escaped) will crossover to receive ustekinumab 45 or 90 mg SC at Weeks 24 and 28 followed by every 12 weeks up to Week 52. At Week 16, participants in placebo group with \< 10% improvement from baseline in both total back pain and morning stiffness measures at Week 12 and 16 will enter early escape to receive ustekinumab 45 mg or 90 mg at Weeks 16, 20, and 28 followed by every 12 weeks up to Week 52. At Week 52, participants who achieved inactive disease by ASDAS (ESR) \<1.3 at both Week 40 and 52 will be re-randomized to receive placebo or ustekinumab every 12 weeks up to Week 88. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) \<1.3 at Week 40 or 52 will continue with ustekinumab every 12 weeks up to Week 88.
Trial: NCT03365622
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Intravenous doses will consist of a single 1,000mg/100 ml IV dose with contents of commercial vials transferred to an empty sterile IV bag.
Trial: NCT03365622
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg acetaminophen tablet ,2 capsules oral every six hours for 24 hours
Trial: NCT03365622
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Intravenous doses will consist of 100ml of normal saline transferred to an empty sterile IV bag.
Trial: NCT03365622
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, opaque capsules that have been filled with inert powder (lactose USP), 2 capsules oral every six hours for 24 hours
Trial: NCT04313868
Drug: GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)
RxNorm normalized name: Thymidine
DrugBank: Thymidine (DB04485)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEN2 is an investigational drug combining cytotoxic and immunotherapy.
Trial: NCT01325233
Drug: PG2
RxNorm normalized name: Fossaoprin SPG2 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder for Injection, 500 mg PG2/500 ml normal saline, tiw, 2 weeks
Trial: NCT01325233
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml normal saline, tiw, 2 weeks
Trial: NCT02571816
Drug: ASP2215
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03823534
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An IV normal saline placebo prepared by the hospital pharmacy.
Trial: NCT03823534
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetaminophen 500 mg PO Q4 hours PRN for mild pain
Trial: NCT03823534
Drug: Oxycodone Acetaminophen
RxNorm normalized name: acetaminophen / oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxycodone-acetaminophen 5-325 mg PO Q4 hours PRN for moderate to severe pain
Trial: NCT03823534
Drug: Hydrocodone/Acetaminophen
RxNorm normalized name: hydrocodone/acetaminophen 5 mg-500 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At discharge, patients will be prescribed 1-2 hydrocodone-acetaminophen 5-325 mg Q4 hours. Those with preexisting liver disease will be prescribed the equivalent in oxycodone.
Trial: NCT02452242
Drug: ABX464
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25, 50, 75, 100, 150 mg, i.e. 1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks
Trial: NCT02507323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00460785
Drug: Opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00881738
Drug: Clarithromycin 250 mg Tablets (Geneva, USA)
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04587908
Drug: TAS-205 [Ambulatory Cohort] [Non-ambulatory Cohort]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ・Treatment period：oral administration for 52 weeks, BID after meal
Trial: NCT05113511
Drug: SCT510
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received a single intravenous infusion (3 mg/kg) of SCT510 for 90 minutes , and the volume of administration was calculated based on the subject's weight.
Trial: NCT00267215
Drug: Lumiracoxib
RxNorm normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02575755
Drug: Azithromycin plus piperaquine phosphate
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04658329
Drug: Antiretroviral
RxNorm normalized name: Antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study the response to antiretroviral treatment (clinical, immuno-virological) and contribute to the identification of the antiretroviral strategies and combinations most suited to the particularities of the infection.
Trial: NCT01480622
Drug: TDF tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White, almond-shaped, film-coated tablets, one side with the markings GILEAD and 4331
Trial: NCT02498301
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered twice daily or once daily with rifaximin depending on which experimental arm they are randomized to